Legal status · United States
Is BI 1820237 legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. BI 1820237 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 2 human studies are cited on its profile.
BI 1820237 in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| Note | Phase 1 completed. Studied alone, with low-dose liraglutide, and in combination with survodutide. |
| FDA approval status | Investigational. Phase 1 published, plus a combination study with survodutide. |
| Human studies cited | 2 of 3 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the BI 1820237 profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
BI 1820237 is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What BI 1820237 is
A first-in-human study in 95 men that found the thing combination therapy has to worry about: its effect on gastric emptying was additive with liraglutide, which is where the nausea comes from.
Boehringer Ingelheim's entry into the same pathway as the PYY analogue, aimed at the same problem: GLP-1 drugs cause gastrointestinal side effects and some people do not respond to them, so a second satiety receptor is worth targeting. The phase 1 result is mostly a tolerability story, and a specific one.
Mechanism: A peptidic agonist at neuropeptide Y receptor type 2, the same receptor PYY(3-36) acts through. Y2 is presynaptic and inhibitory on hypothalamic neuropeptide Y neurons, so agonising it reduces appetite drive.
Regulatory history: Investigational. Phase 1 published, plus a combination study with survodutide.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for BI 1820237 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
BI 1820237 in other countries
Frequently asked questions
Is BI 1820237 legal in the United States?
No. BI 1820237 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 2 human studies are cited on its profile. Note: Phase 1 completed. Studied alone, with low-dose liraglutide, and in combination with survodutide.
Can I buy BI 1820237 in the United States?
No approved product exists to buy. In the United States BI 1820237 is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: Phase 1 completed. Studied alone, with low-dose liraglutide, and in combination with survodutide.
Is BI 1820237 FDA approved?
No. FDA status: Investigational. Phase 1 published, plus a combination study with survodutide.. Current US classification: "Investigational, not approved". On the evidence, 2 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for BI 1820237 live on its compound profile.
BI 1820237 profileThis page is general information about the regulatory status of BI 1820237 in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.